Companies

See how salaries can vary from company to company

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant... view company details

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase 3 TIVO-3 trial of tivozanib for the treatment of RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) i... view company details

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ss-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder. The company's product candidates in oncology include bb2121 and bb21217, which are chimeric antigen recep... view company details

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyo... view company details

Halozyme Therapeutics, Inc., a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. The company's products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal ... view company details

Inovio Pharmaceuticals, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. The company is involved in conducting and planning clinical studies of its proprietary SynCon immunotherapies for human papillom... view company details

Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulati... view company details

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patient... view company details

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead product candidate is TRC105, an endoglin antibody, which is in randomized Phase III clinical trial for angiosarcoma; Phase I/II clinical trial for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trial for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trial for wet AMD. The company also develops TRC102, a small molecule t... view company details

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which completed Phase III clinical trials for the treatment of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia. The company is also developing and sotatercept for the treatment of patients with pulmonary hypertension. In addition, the company is developing... view company details

ALR Technologies Inc. develops compliance monitoring systems that enable health care professionals to remotely monitor patient health conditions in the United States. The company's product includes Diabetes Management System, which consists of a communications software platform that enables health professionals to monitor the health progress of patients with diabetes. It focuses on marketing its products primarily to health care organizations; pharmaceutical companies; insulin providers and other health care companies; providers of health insurance; and providers of disease and case management... view company details

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod (APD334) for ulcerative colitis, and Crohn's disease, as well as for atopic dermatitis and other indications; and Olorinab (APD371), which is in Phase II trial for the treatment of gastrointestinal pain. It is also developing APD418, a calcium-independent myofilament derepressor for the treatment... view company details

Applied Minerals, Inc. extracts, processes, and markets halloysite clay and iron oxide. The company owns the Dragon mine property that consists of 38 patented and 6 unpatented mining claims covering an area of 267 acres located in Juab County, Utah. It offers halloysite clay-based line of products for use in various applications, such as molecular sieves and catalysts, flame retardant additives for plastics, binders for ceramics, nucleation and/or reinforcement of polymers, paints and coatings, cement, batteries, controlled release carriers cosmetics, and others under the tradename DRAGONITE. ... view company details

ATRM Holdings, Inc., through its subsidiaries, manufactures and sells modular buildings for commercial and residential applications in the New England states. It offers multi-unit residential buildings, such as apartment buildings, condominiums, townhouses, and dormitories; and commercial structures, including hospitals, office buildings, and other structures. The company also manufactures structural wall panels, permanent wood foundation systems, and other engineered wood products for use in the construction of residential and commercial buildings, as well as operates a retail lumber yard. It... view company details

ARCA biopharma, Inc. is a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of a preclinical plan for AB171, a new chemical entity for the treatment of various cardiovascular indications, such as p... view company details

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery system for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase IIB clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; that has completed Phase IIa clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary di... view company details

Biglari Holdings Inc., through its subsidiaries, primarily operates and franchises restaurants in the United States. The company owns, operates, and franchises restaurants under the Steak n Shake and Western Sizzlin names. As of December 31, 2018, it operated 413 Steak n Shake company-operated restaurants and 213 franchised units; and 4 Western Sizzlin company-operated restaurants and 55 franchised units. The company also engages in underwriting commercial trucking insurance, and selling physical damage and non-trucking liability insurance to truckers. In addition, it publishes and sells magaz... view company details

Cocrystal Pharma, Inc., a clinical stage biotechnology company, engages in discovering and developing various novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. It employs structure-based technologies to create antiviral drugs. The company's products include CC-31244, a Phase IIa ready broad-spectrum novel non-nucleoside replication inhibitor for the treatment of hepatitis C virus; and CC-42344, a novel PB2 inhibitor that is in preclinical development trials for the treatment of influenza. It also has a pipeline of produ... view company details

MRI Interventions, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging guidance. It offers ClearPoint system, a neuro-navigation system designed for placing catheters, electrodes, and laser fibers to treat various neurological diseases and conditions, as well as for performing biopsies. The company has a strategic agreement with Voyager Therapeutics, Inc. for the neurosurgical device servic... view company details

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Its principal development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver diseas... view company details